Marinus Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Marinus Pharmaceuticals, Inc. - overview
Established
2003
Location
Radnor, PA, US
Primary Industry
Pharmaceuticals
About
Based in Pennsylvania, US, and founded in 2003, Marinus Pharmaceuticals, Inc. operates as a pharmaceutical manufacturing company that develops treatments for neurological and psychiatric disorders like status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder. In March 2022, Marinus Pharmaceuticals, Inc. raised USD 30 million in venture debt financing led by Oaktree Capital Management.
As of November 2022, Scott Braunstein, M. D. is the Chief Executive Officer (CEO) of the company. Marinus Pharmaceuticals, Inc.
focused on the development of new treatments for epilepsy and neuropsychiatric disorders and improves the treatment methodology for patients by developing the treatment of Status Epilepticus (SE), CDKL5 Deficiency Disorder (CDD), Tuberous Sclerosis Complex (TSC), and PCDH19 pediatric epilepsy. The company plans to use March 2022 funds for ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with CDKL5 deficiency (CDD) in patients 2 years of age and older.
Current Investors
Domain Associates, Sofinnova Investments, Canaan Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.marinuspharma.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Marinus Pharmaceuticals, Inc. - timeline of key events
Marinus Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (11,911,000) | (24,414,000) | (28,212,000) | (18,941,000) | (37,131,000) | (54,152,000) | (67,600,000) | - | - | - |
| Operating Income (USD) | (11,920,000) | (24,432,000) | (28,242,000) | (19,043,000) | (37,179,000) | (54,422,000) | (67,937,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (10,833,000) | (24,850,000) | (28,643,000) | (18,898,000) | (36,726,000) | (54,121,000) | (67,475,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - |
Marinus Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Public to Private, Trade Sale | Completed | Marinus Pharmaceuticals, Inc. | - | ||||||||
| Buyout | Completed | Marinus Pharmaceuticals, Inc. | - | ||||||||
| Unspecified Exit | Completed | Marinus Pharmaceuticals, Inc. | - |
Displaying 1 - 3 of 3
Marinus Pharmaceuticals, Inc. - employee data
Marinus Pharmaceuticals, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board, Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.